PUBLISHER: IMARC | PRODUCT CODE: 1467887
PUBLISHER: IMARC | PRODUCT CODE: 1467887
The global allergy treatment market size reached US$ 22.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 35.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.
Allergy treatment is a preventive medical cure for abnormal reactions to allergens, such as pollens, molds, animal dander, latex, insects, food, and medications. They trigger the release of histamine by the immune system that causes inflammation, rashes, itchiness, sneezing, runny nose, and red eyes. They can also cause various allergic conditions, including hay fever, asthma, rhinitis, and skin, food, and eye allergies. Allergy treatment includes anti-allergic drugs and immunotherapy that can be administered through oral, inhalers, and intranasal dosage forms. These treatment methods help reduce sensitivity and inflammation, decrease symptoms, and improve the quality of the patient's life.
The increasing prevalence of various allergies across the globe is one of the primary factors driving the market growth. In line with this, favorable initiatives by governments and non-governmental organizations (NGOs) to sensitize the masses about the adversities of allergies and their appropriate treatment options are favoring the market growth. Furthermore, increasing demand for over-the-counter (OTC) drugs, coupled with a growing inclination toward self-medication among consumers, is acting as another growth-inducing factor. Additionally, the integration of artificial intelligence (AI), natural language processing (NLP), and machine learning (ML) for diagnosing allergic diseases, predicting patient outcomes for targeted interventions, analyzing immunological data, and improving care delivery is providing an impetus to market growth. Apart from this, the increasing demand for subcutaneous allergen-specific immunotherapy (SCIT) due to its effectiveness, safety, and ability to alter the immune system and provide systemic relief is creating a positive outlook for the market. Other factors, including significant healthcare expenditures, increasing geriatric population, extensive research and development (R&D) activities towards novel treatments, and rising incidences of asthma, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global allergy treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, treatment, dosage form and distribution channel.
Eye Allergy
Skin Allergy
Food Allergy
Asthma
Rhinitis
Others
Anti-Allergy Drugs
Immunotherapy
Oral
Inhalers
Intranasal
Others
Hospital Pharmacies
Retail Pharmacies
Online Retailers
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., ALK-Abello A/S, Allergopharma (Dermapharm AG), Allergy Therapeutics, Almirall S.A, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, HAL Allergy Group (Droege International Group), Leti Pharma, Nicox S.A., Sanofi S.A. and Stallergenes Greer.